Biologica Technologies introduced OsseoGEN growth factor enriched cellular bone matrix (CBM). OsseoGEN CBM contains osteoconductivity, osteoinductivity and osteogenicity and is supplied via an open-bore syringe for easy dispensing.
Like the company’s ProteiOS product, OsseoGEN contains osteoinductive, angiogenic and mitogenic growth factors. OsseoGEN is DMSO-free, eliminating the need to rinse and decant the tissue prior to implantation, and can be thawed in half the time of competitive CBMs.
“We are excited to bring this innovative bone graft to the market and demonstrate clinical efficacy in a segment of the market that lacks sufficient clinical proof,” said Amit Govil, President of Biologica Technologies. “We feel that the growth factor enrichment processes that are utilized to produce OsseoGEN will provide surgeons with another option to improve patient outcomes.”
Biologica Technologies introduced OsseoGEN growth factor enriched cellular bone matrix (CBM). OsseoGEN CBM contains osteoconductivity, osteoinductivity and osteogenicity and is supplied via an open-bore syringe for easy dispensing.
Like the company's ProteiOS product, OsseoGEN contains osteoinductive, angiogenic and mitogenic growth...
Biologica Technologies introduced OsseoGEN growth factor enriched cellular bone matrix (CBM). OsseoGEN CBM contains osteoconductivity, osteoinductivity and osteogenicity and is supplied via an open-bore syringe for easy dispensing.
Like the company’s ProteiOS product, OsseoGEN contains osteoinductive, angiogenic and mitogenic growth factors. OsseoGEN is DMSO-free, eliminating the need to rinse and decant the tissue prior to implantation, and can be thawed in half the time of competitive CBMs.
“We are excited to bring this innovative bone graft to the market and demonstrate clinical efficacy in a segment of the market that lacks sufficient clinical proof,” said Amit Govil, President of Biologica Technologies. “We feel that the growth factor enrichment processes that are utilized to produce OsseoGEN will provide surgeons with another option to improve patient outcomes.”
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
